Latest Views & News

Barkby – The (Not Very Good) Pump Before The Dump?

By Nigel Somerville, the Deputy Sheriff of AIM | Thursday 3 March 2022


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


AIM-listed Barkby Group (BARK) has announced the completion of a clinical study by Verso Biosense, a minority shareholding of the company. There were, natch, no numbers from this missive from a lookalike of the Adam Reynolds keyboard, so it is hardly an RNS released to inform shareholders…..but then, it is an RNS Reach.

You must be a registered member to read this story
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £5.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Monday »

Tom

Just 26 days to go: Book Now!

Sunday »

Beggar

Me and “The Millionaire Next Door”

Tuesday »

SNX

Synectics – a recovery Buy?

 

GetAFix

Malcolm Stacey is Moving House

Monday »

WG

Wood Group - a Buy (again)?

 

Bear

Video: Bubbles always implode